Mumbai based pharmaceutical company, Cipla got approval from the Indian regulators to experiment medicine, Favipiravir for COVID-19 in India.
Around the globe, a lot of drugs are under clinical trials phases on corona virus patients, in order to develop some success against COVID-19. CSIR (Council of Scientific and Industrial Research) has identified top 25 drugs for repurposing. From these 25 drugs, Favipiravir has the most promising outcomes or results.
Favipiravir is a broad spectrum inhibitor, an anti viral drug which was also used to treat influenza virus in Japan in 2014. In relation to COVID-19, Favipiravir has shown results against RNA viruses for which we don’t have a treatment yet.
Latest new on Pharmaceutical Companies in India
DCGI (Drug Controller General of India) has given permissions to Mumbai-based Glenmark Pharmaceuticals to perform trials with Favipiravir on mild to moderate patients suffering from COVID-19.
Cipla had also applied for the approval and finally got a green signal to conduct trials.
According to the recent news, Glenmark will administer Favipiravir in 150 COVID-19 patients and will do the comparison with the patients undergoing regular and standard treatment.
Another development which was seen recently, on Wednesday was, Strides Pharma Science Ltd had developed Favipiravir antiviral tablets and had applied to the authorities to begin trials.
I hope this Favipiravir drug works like wonders and help come over corona phase.
I’ll keep you guys updated.